Summary
0SGC Chart
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical trial, AB-101, an oral PD-L1 inhibitor, has shown to be generally safe and well-tolerated with evidence of high receptor occupancy and no liver dysfunction in cHBV patients WARMINSTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the presentation of five posters, including one late-breaker, highlighting imdusiran, its RNAi therapeutic and AB-101, its oral PD-L1 inhibitor, at the European Association for the Study of the Liver (EASL) Congress 2025.
Arbutus Biopharma Corporation (0SGC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Arbutus Biopharma Corporation ever had a stock split?
Arbutus Biopharma Corporation Profile
| Biotechnology Industry | Healthcare Sector | Ms. Lindsay Androski J.D., M.B.A. CEO | LSE Exchange | CA03879J1003 ISIN |
| US Country | 44 Employees | - Last Dividend | 4 Nov 2010 Last Split | 3 Aug 2015 IPO Date |
Overview
Arbutus Biopharma Corporation, originally known as Tekmira Pharmaceuticals Corporation until its rebranding in July 2015, is a biopharmaceutical entity involved in the development of innovative treatments for the chronic Hepatitis B virus (HBV) infection primarily within the United States. Headquartered in Warminster, Pennsylvania, Arbutus is dedicated to pioneering new therapeutics that promise a brighter future for individuals battling HBV. Their scientific endeavors extend beyond HBV, venturing into small molecule antiviral medicines aimed at various coronaviruses, including COVID-19, marking their commitment to addressing global viral challenges. Arbutus's strategic alliances with esteemed organizations such as Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc., along with a clinical collaboration with Barinthus Biotherapeutics plc, underscore their prominent role in the biopharmaceutical landscape.
Products and Services
- Imdusiran (AB-729)
- AB-101
- Small Molecule Antivirals for Coronaviruses
- Clinical Collaboration with Barinthus Biotherapeutics plc to Evaluate VTP-300
A cutting-edge, proprietary RNAi therapeutic that is administered subcutaneously. Imdusiran is targeted at suppressing HBV antigens across the board, including HBsAg, a crucial element in the persistence and replication of the virus in infected individuals. This promising candidate stands at the forefront of Arbutus's HBV pipeline, exemplifying their innovative approach to tackling hepatitis B virus infection.
An oral PD-L1 inhibitor currently under development, AB-101 represents another facet of Arbutus’s therapeutic arsenal against HBV. This novel compound aims to reignite the patient's own HBV-specific immune system, showcasing a unique therapeutic approach by leveraging the body’s inherent defense mechanisms to combat the virus.
In response to the global emergency triggered by the coronavirus pandemic, Arbutus has expanded its research and development to include small molecule antivirals targeting not just HBV but also coronaviruses, including COVID-19. This initiative reflects Arbutus’s flexibility and their commitment to contributing significant solutions to pressing global health crises.
The partnership with Barinthus Biotherapeutics plc to assess VTP-300 signifies a strategic collaboration aimed at discovering potent therapeutic options. This-in-progress evaluation underscores the dedication of Arbutus to explore collaborative opportunities that can enhance their product offerings and potentially lead to novel treatment paradigms.
Contact Information
